Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates

Group 1 - Adaptive Biotechnologies reported a quarterly loss of $0.17 per share, better than the Zacks Consensus Estimate of a loss of $0.24, and improved from a loss of $0.26 per share a year ago, resulting in an earnings surprise of +29.17% [1] - The company achieved revenues of $58.88 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 18.47%, and up from $43.19 million in the same quarter last year [2] - Adaptive Biotechnologies shares have increased approximately 82% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.6% [3] Group 2 - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The trend of estimate revisions for Adaptive Biotechnologies was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] - The current consensus EPS estimate for the upcoming quarter is -$0.21 on revenues of $56.63 million, and for the current fiscal year, it is -$0.87 on revenues of $218.28 million [7] Group 3 - The outlook for the Medical - Biomedical and Genetics industry, where Adaptive Biotechnologies operates, is currently in the bottom 43% of over 250 Zacks industries, which may impact stock performance [8]